CCT007093
Modify Date: 2025-08-22 06:34:51
CCT007093 structure
|
Common Name | CCT007093 | ||
|---|---|---|---|---|
| CAS Number | 176957-55-4 | Molecular Weight | 272.385 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 484.7±45.0 °C at 760 mmHg | |
| Molecular Formula | C15H12OS2 | Melting Point | 222-223℃ | |
| MSDS | Chinese USA | Flash Point | 246.9±28.7 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of CCT007093CCT 007093 is an effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines.IC50 value: Target: PPM1DAs expected of a specific inhibitor, the toxicity of CCT007093 to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent [1]. Knockdown of WIP1 or treatment with the WIP1 inhibitor CCT007093 results in increased phosphorylation of known WIP1 targets, reduced HDM2 expression, and reduced growth specifically in WIP1 wild-type and high-expressing medulloblastoma cells [2]. CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression [3]. |
| Name | (2Z,5E)-2,5-bis(thiophen-2-ylmethylidene)cyclopentan-1-one |
|---|---|
| Synonym | More Synonyms |
| Description | CCT 007093 is an effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines.IC50 value: Target: PPM1DAs expected of a specific inhibitor, the toxicity of CCT007093 to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent [1]. Knockdown of WIP1 or treatment with the WIP1 inhibitor CCT007093 results in increased phosphorylation of known WIP1 targets, reduced HDM2 expression, and reduced growth specifically in WIP1 wild-type and high-expressing medulloblastoma cells [2]. CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 484.7±45.0 °C at 760 mmHg |
| Melting Point | 222-223℃ |
| Molecular Formula | C15H12OS2 |
| Molecular Weight | 272.385 |
| Flash Point | 246.9±28.7 °C |
| Exact Mass | 272.032959 |
| PSA | 73.55000 |
| LogP | 5.18 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.748 |
| Storage condition | 2~8°C |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3.0 |
|
Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to γ-radiation.
Cell Death Dis. 4 , e744, (2013) Wild-type p53-induced phosphatase 1 (Wip1) is a p53-inducible serine/threonine phosphatase that switches off DNA damage checkpoint responses by the dephosphorylation of certain proteins (i.e. p38 mito... |
|
|
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
Breast Cancer Res. 12 , R41, (2010) Paclitaxel is a widely used drug in the treatment of patients with locally advanced and metastatic breast cancer. However, only a small portion of patients have a complete response to paclitaxel-based... |
| Cyclopentanone, 2,5-bis(2-thienylmethylene)-, (2E,5E)- |
| (2E,5E)-2,5-Bis(2-thienylmethylene)cyclopentanone |
| (2E,5E)-2,5-bis(thiophen-2-ylmethylidene)cyclopentanone |
| CCT007093 |